Phase-I Study Evaluating the Pharmacokinetic Profile of RhuDex®

Inclusion Criteria: * Healthy male subjects between 18 and 60 years at the time of enrollment * Male volunteers and their partners who are of child-bearing potential must agree to use a double-barrier method of contraception during the study and for 12 weeks after discharge * BMI between 18.5 and 29.9 kg/m² * Written informed consent * Ability to comply with the requirements of the study Exclusion Criteria: * Acute infection at time of enrollment * History of chronic inflammation, chronic infection, other chronic disease, autoimmune disorders (e.g. diabetes mellitus) or cancer * Clinical significant abnormal ECG * Clinical significant abnormal laboratory values (especially in terms of liver or renal insufficiency) * Clinically significant physical findings * Major surgery within the last 4 weeks prior to enrollment * Organ allograft recipient * Concomitant or planned treatment which would interfere with study results * Any systemic medical treatment, including over the counter products and dietary supplements such as iodine, fluoride or vitamins, within one week before and during the study course * Known allergy against any ingredient of the study medication or meglumine * Participation in an investigational trial within 30 days prior to enrollment * Systemic intake of immunosuppressive or immunomodulatory medication or vaccination within 30 days prior to enrollment and for the whole study duration * Blood loss exceeding 450 mL (including blood donations) within 12 weeks prior to enrollment into the study * Medical history of alcohol or drug abuse or alcohol consumption greater than 21 units per week for males. A unit of alcohol is equivalent to: half a pint of average strength beer (280 mL), a glass (125 mL) of wine or a standard measure (25 mL) of spirits, sherry or port * A positive alcohol breath test * A positive urine drug screen * Regular smokers (more than 20 cigarettes or 5 cigars per day) * Presence of hepatitis B surface antigen (HBsAG), hepatitis C antibody (HCV Ab) or HIV-1 or HIV-2 antibodies at screening